Question 1

What are the potential benefits of participating in this trial compared to standard treatments?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer clinical trial (NCT00251433). Contact the study team or your healthcare provider for specific answers.

Question 2

What side effects should I expect from the combination of these drugs?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer clinical trial (NCT00251433). Contact the study team or your healthcare provider for specific answers.

Question 3

How often would I need to come in for treatment and monitoring?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer clinical trial (NCT00251433). Contact the study team or your healthcare provider for specific answers.

Question 4

What tests will be done to evaluate my response to the treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer clinical trial (NCT00251433). Contact the study team or your healthcare provider for specific answers.

Question 5

Are there any specific eligibility requirements I should be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer clinical trial (NCT00251433). Contact the study team or your healthcare provider for specific answers.

Question 6

What happens if I experience side effects or my condition worsens during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer clinical trial (NCT00251433). Contact the study team or your healthcare provider for specific answers.

What this study is about